Have a feature idea you'd love to see implemented?
Let us know!
MRNS Marinus Pharmaceuticals Inc
Price (delayed)
$0.3223
Market cap
$17.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.47
Enterprise value
$69.99M
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts
Highlights
MRNS's debt is down by 12% YoY
The EPS has grown by 11% YoY and by 7% from the previous quarter
The net income is up by 6% since the previous quarter but it has declined by 4.9% year-on-year
The gross profit has contracted by 4.2% YoY but it has grown by 3.4% from the previous quarter
The company's quick ratio has shrunk by 77% YoY and by 30% QoQ
The equity has declined by 41% since the previous quarter
Key stats
What are the main financial stats of MRNS
Market
Valuations
Earnings
Shares outstanding
55.19M
Market cap
$17.79M
Enterprise value
$69.99M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.22
Revenue
$31.47M
EBIT
-$123.39M
EBITDA
-$122.7M
Free cash flow
-$115.93M
Per share
Balance sheet
Liquidity
EPS
-$2.47
Free cash flow per share
-$2.03
Book value per share
-$1.21
Revenue per share
$0.55
TBVPS
$1.11
Total assets
$63.62M
Total liabilities
$130.36M
Debt
$94.39M
Equity
-$66.74M
Working capital
$22.9M
Debt to equity
-1.41
Current ratio
1.66
Quick ratio
1.33
Net debt/EBITDA
-0.43
Margins
Efficiency
Dividend
EBITDA margin
-390%
Gross margin
90.2%
Net margin
-446.5%
Operating margin
-395.9%
Return on assets
-122.4%
Return on equity
N/A
Return on invested capital
-129.1%
Return on capital employed
-423.7%
Return on sales
-392.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRNS stock price
How has the Marinus Pharmaceuticals stock price performed over time
Intraday
4.3%
1 week
4.41%
1 month
-82.29%
1 year
-94.57%
YTD
-97.03%
QTD
-81.69%
Financial performance
How have Marinus Pharmaceuticals's revenue and profit performed over time
Revenue
$31.47M
Gross profit
$28.37M
Operating income
-$124.57M
Net income
-$140.49M
Gross margin
90.2%
Net margin
-446.5%
The company's operating margin rose by 11% QoQ and by 2.2% YoY
MRNS's net margin is up by 9% QoQ but it is down by 3.2% YoY
The company's operating income rose by 8% QoQ
The net income is up by 6% since the previous quarter but it has declined by 4.9% year-on-year
Growth
What is Marinus Pharmaceuticals's growth rate over time
Valuation
What is Marinus Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
0.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.22
The EPS has grown by 11% YoY and by 7% from the previous quarter
The equity has declined by 41% since the previous quarter
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 174.1 and 94% lower than the last 4 quarters average of 10.6
MRNS's revenue is up by 4% since the previous quarter
Efficiency
How efficient is Marinus Pharmaceuticals business performance
The company's return on assets has shrunk by 103% YoY and by 22% QoQ
The ROIC has dropped by 50% year-on-year and by 7% since the previous quarter
The ROS has grown by 10% from the previous quarter but it has contracted by 3.3% YoY
Dividends
What is MRNS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRNS.
Financial health
How did Marinus Pharmaceuticals financials performed over time
The total assets is 51% less than the total liabilities
The company's quick ratio has shrunk by 77% YoY and by 30% QoQ
Marinus Pharmaceuticals's current ratio has plunged by 74% YoY and by 27% from the previous quarter
Marinus Pharmaceuticals's debt to equity has shrunk by 172% YoY but it has increased by 30% QoQ
The equity has declined by 41% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.